A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Qu, Xiaoyu ^a   Randhawa, Grace ^b   Friedman, Cynthia ^b   Kurland, Brenda F ^a   Glaskova, Lena ^b   Coleman, Ilsa ^a   Mostaghel, Elahe ^a,c   Higano, Celestia S ^a,b,c   Porter, Christopher ^d   Vessella, Robert ^c,e   Nelson, Peter S ^a,c   Fang, Min ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e Puget Sound VA Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

AR GENE; ARTICLE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CHROMOSOME ABERRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ERG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; GENE FUSION; GENE LOCUS; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOLECULAR PROBE; ONCOGENE; PROTEIN EXPRESSION; PTEN GENE; RISK ASSESSMENT; TMPRSS2 GENE; TUMOR XENOGRAFT;

CHROMOSOME ABERRATIONS; GENE AMPLIFICATION; GENE DELETION; GENE REARRANGEMENT; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOGISTIC MODELS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; SERINE ENDOPEPTIDASES;

EID: 84884790690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074671     Document Type: Article

References (38)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
2. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, et al. (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27: 253-263.
3. Clark JP, Cooper CS, (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439.
4. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, et al. (2009) TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69: 1400-1406.
5. Esgueva R, Perner S, C JL, Scheble V, Stephan C, et al. (2010) Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 23: 539-546.
6. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
7. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, et al. (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806.
8. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, et al. (2007) FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97: 678-685.
9. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, et al. (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218: 505-513.
10. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, et al. (2008) Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21: 1451-1460.
11. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, et al. (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102: 678-684.
12. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575-586.
13. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, et al. (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804.
14. Wang Y, Romigh T, He X, Tan MH, Orloff MS, et al. (2011) Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30: 4327-4338.
15. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, et al. (2008) Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 25: 377-388.
16. Corey EV, R. (2007) Xenograft Models of Human Prostate Cancer. In: Chung LWK IW, amd Simons JW, editor. Contemporary Cancer Research: Prostate Cancer: Biology, Genetics, and the New Therapeutics. Totowa: Humana Press. pp. 3-31.
17. Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, et al. (2013) A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Cancer Genet 206: 1-11.
18. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, et al. (2010) The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 120: 4478-4492.
19. Zeger SL, Liang KY, Albert PS, (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics 44: 1049-1060.
20. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, et al. (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 4: 649-654.
21. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243.
22. FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, et al. (2008) Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 8: 230.
23. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, et al. (2009) Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 69: 7793-7802.
24. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, et al. (2008) Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68: 3584-3590.
25. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341.
26. Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, et al. (2008) Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 68: 5599-5608.
27. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, et al. (2006) The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 208: 699-707.
28. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, et al. (2006) Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169: 128-137.
29. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, et al. (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526.
30. Gallucci M, Merola R, Leonardo C, De Carli P, Farsetti A, et al. (2009) Genetic profile identification in clinically localized prostate carcinoma. Urol Oncol 27: 502-508.
31. Gallucci M, Merola R, Farsetti A, Orlandi G, Sentinelli S, et al. (2006) Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma. Cancer Lett 237: 76-82.
32. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, et al. (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198: 237-244.
33. Ford OH, (2003) Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170: 1817-1821.
34. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, et al. (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 35: 1014-1020.
35. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
36. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, et al. (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15: 559-565.
37. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, et al. (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34: 646-653.
38. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, et al. (2012) Exome Sequencing of Prostate Cancer Supports the Hypothesis of Independent Tumour Origins. Eur Urol.